Malnutrition Clinical Trial
Official title:
A Single-arm Open-label Safety Study of SMOFlipid to Evaluate the Risk of Developing Essential Fatty Acid Deficiency (EFAD) and/or Parenteral Nutrition-associated Cholestasis (PNAC) in Pediatric Patients 1 Month to 17 Years of Age and in Adult Patients, Who Are Anticipated to Need 8 Weeks or Longer of Parenteral Nutrition Treatment
Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipid.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | September 2026 |
Est. primary completion date | March 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 17 Years |
Eligibility | Age Limits: and Adults Inclusion Criteria: 1. Male or female patients, at least 1 month of age. 2. Patients who require PN for at least 5 days/week. 3. Patients who receive 80% or more of their total energy requirements as PN at enrollment and who are expected to receive 80% or more of their total energy requirements as PN for at least 56 days. 4. Written informed consent. In case of pediatric patients, informed consent must be obtained from parent(s) or legal representatives. If possible, the assent of the pediatric patient must also be obtained (according to local law). Exclusion Criteria: 1. Use of any other lipid injectable emulsion than SMOFlipid within 6 months prior to study participation 2. Known hypersensitivity to fish, egg, soybean, or peanut proteins, or to any of the active ingredients or excipients of SMOFlipid. 3. Hyperlipidemia or disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration >250 mg/dL in infants or >400 mg/dL in older pediatric and adult patients). 4. Inborn errors of amino acid metabolism. 5. Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support). 6. Hemophagocytic syndrome. 7. Liver enzymes (either AST, or ALT, or GGT) exceeding 2 x upper limit of normal range 8. Direct bilirubin exceeding 2 x upper limit of normal range 9. INR exceeding 2 x upper limit of normal range and patient not receiving oral anticoagulants. 10. Any known hepatic condition outside of IFALD that will increase direct bilirubin =2.0 mg/dL. 11. Clinically significant abnormal levels of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate). 12. Active bloodstream infection demonstrated by positive blood culture at screening. 13. Severe renal failure (eGFR <15 ml/min per 1.73 m2) including patients on renal replacement therapy. 14. Abnormal blood pH, oxygen saturation, or carbon dioxide. 15. Pregnancy or lactation. 16. Participation in another interventional clinical study. 17. Unlikely to survive longer than 56 days. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Fresenius Kabi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of PNAC | defined as direct bilirubin level > 2 mg/dL, confirmed by a second sample collected 7 days after the first sample | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | |
Primary | Time to direct bilirubin > 2mg/dL | (confirmed by a second sample collected 7 days after the first) | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | |
Primary | Incidence of EFAD | Triene/tetraene ratio in total plasma to assess EFAD (Holman 1960), Severity of EFAD will be graded based on triene/tetraene ratio, as suspected = 0.05, moderate = 0.20 and severe = 0.40 (Cober et al 2012) | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | |
Primary | Incidence of clinical EFAD | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Primary | Fatty acids | analyzed in total plasma, including linoleic acid, a-linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid and Mead acid | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | |
Secondary | Laboratory values: triglycerides | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: direct bilirubin | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: total bilirubin | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: alanine aminotransferase (ALT) | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: aspartate aminotransferase (AST) | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: gamma-glutamyl transferase (GGT) | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: alkaline phosphatase (ALP) | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: creatinine | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: urea nitrogen | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: electrolytes | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: glucose | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values: total protein | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values hematology: white blood cell count (WBC), red blood cell count (RBC), and platelet count | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values hematology: Hemoglobin | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values hematology Hematocrit | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Laboratory values hematology: International normalized ratio | At baseline before start of treatment to assess eligibility | ||
Secondary | Vital signs: Blood pressure | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Vital signs: Heart rate | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Vital signs: Body temperature | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | Incidence of adverse events | Start of Treatment until After End of Last Study PN (+6 months for pediatric patients). Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). | ||
Secondary | BMI | BMI is the weight in kilograms divided by height in meters squared. Alternatively, BMI can be calculated by dividing the weight in kilograms by the height in centimeters squared, and then multiplying the result by 10,000. | Start of Treatment until After End of Last Study PN Duration of Treatment: Study treatment will last for a minimum of 8 weeks (56 consecutive days) and as long as PN is indicated, up to 1 year (365 consecutive days). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT03268902 -
Early Life Interventions for Childhood Growth and Development In Tanzania
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04746664 -
Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia
|
N/A | |
Completed |
NCT04608656 -
Livestock for Health Project
|
N/A | |
Completed |
NCT06009198 -
Nutritional, and WASH Related Education Intervention to Address Malnutrition of Early Adolescents in Pakistan
|
N/A | |
Recruiting |
NCT05417672 -
Assessment of Relationship Between Preoperative Nutritional Status and Perioperative/Postoperative Conditions in Patients With Lung Cancer Scheduled for Lobectomy
|
||
Recruiting |
NCT05257980 -
Evaluation of Four New Ready to Drink Oral Nutritional Supplements: Adult ONS Trial
|
N/A | |
Completed |
NCT03628196 -
A Nutrition-Focused QIP in Outpatient Clinics
|
||
Completed |
NCT05015647 -
Low Protein Diet in CKD Patients at Risk of Malnutrition
|
N/A | |
Enrolling by invitation |
NCT04675229 -
Extending the Validation of SCREEN to Persons Living With Dementia or in Retirement Homes
|
||
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Not yet recruiting |
NCT05860556 -
Sustainable Eating Pattern to Limit Malnutrition in Older Adults
|
||
Not yet recruiting |
NCT06047054 -
Incidence Rate and Risk Factors of Malnutrition in ICU
|
||
Not yet recruiting |
NCT04398836 -
Preoperative Nutrition for Crohn's Disease Patients
|
Phase 3 | |
Not yet recruiting |
NCT04183075 -
Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Patients With Spontaneous Hip Fracture
|
N/A | |
Not yet recruiting |
NCT03150927 -
Clinical Study of Novel Probiotic Microbial Compositeā¢ to Treat Undernourished Young Children
|
N/A | |
Recruiting |
NCT03408067 -
Evaluation of the Efficacy of Nutritional Risk Screening Tests, NRS 2002 and SGA, to Identifying Malnourished Patients
|
N/A | |
Recruiting |
NCT02833740 -
Comparing Performance of Simplified Mid-Upper Arm Circumference Devices ("Click-MUACs") to Detect Acute Malnutrition
|
N/A | |
Completed |
NCT02938247 -
Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Scheduled Intake
|
N/A | |
Completed |
NCT02938234 -
Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Free Intake
|
N/A |